MARKET

XLRN

XLRN

Acceleron
NASDAQ

Real-time Quotes | Nasdaq Last Sale

99.99
-0.69
-0.69%
After Hours: 99.99 0 0.00% 16:00 07/10 EDT
OPEN
100.53
PREV CLOSE
100.68
HIGH
101.96
LOW
99.49
VOLUME
305.42K
TURNOVER
--
52 WEEK HIGH
110.49
52 WEEK LOW
37.60
MARKET CAP
5.84B
P/E (TTM)
-38.5229
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average XLRN stock price target is 123.80 with a high estimate of 140.00 and a low estimate of 88.00.

EPS

XLRN News

More
Acceleron Announces Closing of Public Offering of Common Stock and Exercise of Underwriters Option to Purchase Additional Shares
Business Wire · 3d ago
XLRN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Acceleron Pharma Inc. and Encourages Investors to Contact the Firm
PR Newswire · 4d ago
Acceleron (XLRN) in Focus: Stock Moves 5.3% Higher
Zacks · 4d ago
10 Stocks to Invest in the Health Care Revolution
Kiplinger · 07/01 17:07
Acceleron prices stock offering at $92.50
Seeking Alpha - Article · 07/01 07:24
Acceleron Prices 4.8M Share Public Offering of Common Stock @$92.50/Share
Acceleron Pharma Inc. (Nasdaq: XLRN) today announced that it has priced an underwritten public offering of 4,864,864 shares of common stock at a price to the public of $92.50 per share for gross proceeds of $450.0 million.
Benzinga · 06/30 22:51
The Daily Biotech Pulse: Verrica Flags Potential Regulatory Delay, Back-To-Back FDA Approvals For Merck's Keytruda, OncoCyte Stalls Lung Nodule Malignancy Test
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29)
Benzinga · 06/30 11:41
Acceleron Pharma Reports $400M Common Stock Offering
Benzinga · 06/29 20:01

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About XLRN

Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. It has four internally discovered therapeutic candidates that are in clinical trials, which include luspatercept, sotatercept, dalantercept and ACE-083. It offers a platform technology, IntelliTrap. It is also evaluating ACE-1332, a selective TGF-beta antagonist, for treatment of disorders with a fibrotic component, and additional molecules from its IntelliTrap platform for undisclosed therapeutic areas. Dalantercept is designed to treat cancers by inhibiting blood vessel formation by inhibiting signaling through the ALK1 receptor. ACE-083 is designed to promote muscle growth and function in specific, targeted muscles.
More

Webull offers kinds of Acceleron Pharma Inc stock information, including NASDAQ:XLRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XLRN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XLRN stock methods without spending real money on the virtual paper trading platform.